Demographic data was collected along with biochemical and serological indices.

Statistical analysis was performed using t-tests, with p-values less than 0.05 considered statistically significant. Results: 493 FibroScans® were performed on 448 patients with CHB. Of the 351 patients not on antiviral therapy at time of FibroScan®, 17% were eAg+, with 7% in phase I and 10% in phase II disease. Patients learn more in phase I CHB had a mean ALT of 23 IU/L, mean VL of 1.4 × 108 IU/ml, and mean LSM of 4.66 kPa. Patients in phase II CHB had a significantly higher mean LSM of 8.26 kPa (p = 0.001), with a mean ALT of 86 IU/L and mean VL of 9.6 × 107 IU/ml. Of the 83% of untreated patients with eAg- disease, 44% were in phase

III (VL < 2000 IU/ml, ALT normal) and 13% in phase IV (VL > 2000 IU/ml, ALT raised) respectively. Patients in phase III disease had a mean ALT of 21 IU/L, mean VL of 455 IU/mL, and mean LSM of 5.04 kPa. Patients in phase IV CHB has a significantly higher mean LSM of 7.86 kPa (p < 0.001), with a mean ALT of 71 IU/L and mean VL of 1.1 × 106 IU/ml. Patients with eAg- and VL < 2000 IU/ml but raised ALT (mean 49 IU/L) were found to Veliparib mw have an elevated mean LSM of 7.26 kPa, while eAg- patients with normal ALT but raised VL (mean 1.9 × 105 IU/ml) had a mean LSM of 5.16 kPa. Of 64 patients on CHB therapy at time of FibroScan®, 94% were on oral antivirals with complete viral suppression. Thymidylate synthase Mean LSM was 8.36 kPa and 8.91 kPa in patients on oral antivirals who were eAg+ and eAg- respectively. Treated patients with raised ALT had a higher mean LSM compared to patients with normal ALT (13.2 kPa vs. 7.63 kPa, p = 0.01). Conclusion: FibroScan® LSM was elevated in

CHB patient groups with raised ALT regardless of eAg status or viral load, with eAg+ patients having higher ALT, VL and LSM than eAg- patients. In eAg- patients with viral escape (VL > 2000 IU/ml), having a raised ALT was associated with a significantly higher VL compared to patients with normal ALT. ES GONSALKORALA,1 C TALLIS,2 KA STUART,2 E DUNCAN1 1Royal Brisbane and Women’s Hospital, Brisbane, Australia, 2Department of Gastroenterology and Hepatology, Princess Alexandra Hospital, Brisbane, Australia Introduction: Patients with chronic liver disease (CLD) are at increased risk of low bone mineral density (BMD) known as hepatic osteodystrophy. After liver transplantation patients are at an increased risk of osteoporosis and fracture due to immunosuppression but also exacerbation of pre-existing bone disease. The cause of low BMD in CLD may be multifactorial including nutritional deficiencies and hypogonadism (Alcalde Vargas, Pascasio Acevedo et al. 2012). It is unclear whether anabolic failure or catabolic excess (i.e. excess bone resorption) predominates in hepatic osteodystrophy; of note, almost all treatment options target bone resorption.